4 Penny Stocks to Boost Your Portfolio: BCDA SENS SFIO VXIT

The stock market is finally showing more evident signs of recovery after struggling at the end of January. This is the right time to benefit from the rebound.Right now, one needs to be quick to take profits and go where the opportunities are. For us and our subscribers here at Insider Financial, that means trading both OTC and Nasdaq stocks.Our subscribers have plenty of opportunities in OTC, Nasdaq, and NYSE penny stocks with low floats, news, and a significant short position.Smart investors know that if you want to make the big money off a small account, the place to be is in penny stocks. There are many good penny stocks that can boost your portfolio’s value in the long term. For investors, we preach the key to trading penny stocks is finding momentum BEFORE it happens and ahead of the crowd.[embed]https://www.youtube.com/watch?v=KiEIYm2SnlQ[/embed]We alert our subscribers with our best ideas before our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here.In this article, we take a look at 4 penny stocks that can do well in the following weeks. They are BioCardia, Inc (NASDAQ: BCDA), Senseonics Holdings Inc (NYSE American: SENS), Starfleet Innotech, Inc (OTCPK: SFIO), and VirExit Technologies, Inc (NASDAQ: VXIT). PENNY STOCKS #1 BCDA PENNY STOCKS #2 SENS PENNY STOCKS #3 SFIO PENNY STOCKS #4 VXIT

PENNY STOCKS #1 BCDA

BioCardia, Inc has bounced back on Thursday to recover from the lowest level in years. The NASDAQ-listed stock fell to as low as $1.25 at the end of January and returned to the $2 mark where it ended last year. After breaking above $2.2, the price corrected to the current level at $1.98, up 25% during the last five days. More importantly, the latest bullish move was pushed by the highest volume figure since November 2020.BioCardia is a clinical-stage regenerative medicine company that develops therapeutics for cardiovascular diseases. It has two main therapeutic candidates:

• CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia;
• ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture-expanded bone marrow-derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure.

Besides this, BCDA offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine, as well as Morph deflectable guides and sheaths.The latest price spike came after the company announced that the FDA had granted Breakthrough Device Designation for the CardiAMP Cell Therapy System for the treatment of heart failure. The company says it might be the first cardiac cell therapy to receive FDA Breakthrough Device status.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure. The therapy incorporates a pre-procedural screening assay to identify patients who may be likely responders, a first for cardiac cell therapy, and designed to enhance patient selection. Eligible patients get a high dose of cells using an intramyocardial delivery system that has been shown in published literature to present the lowest risk to patients for biotherapeutic delivery and to be three to six times more efficient at delivering cells to the heart muscle than other methods. This approach allows the patient to be discharged from the hospital the morning after the procedure.https://www.youtube.com/watch?v=bDqcStVREDQCarl Pepine, MD, MACC, Professor in the Division of Cardiovascular Medicine at the University of Florida, said:

“It is exciting for the field of cardiology that the FDA has recognized the potential of a cell therapy to improve the lives of patients struggling with heart failure. Getting this therapy fast-tracked and to patients more quickly than traditional methods would give us new options and a greater armamentarium to assist our patients in need. I am enthusiastic about completing the U.S. pivotal trial of the CardiAMP Cell Therapy to build the body of evidence necessary to support this accelerated FDA path.”

BCDA said that its CardiAMP Cell Therapy System had shown no incidence of mortality at one year in its Phase II trial or in the 10-patient roll-in cohort from the Phase III trial that is currently enrolling. Earlier studies of the therapy have shown statistically significant improvement in exercise tolerance and quality of life.The mechanism of action used by CardiAMP Cell Therapy is different from other therapies focused on transforming stem cells into new heart cells, an approach that has presented patient risks, such as rhythm abnormalities and cell rejection.While BCDA is unprofitable, the company has obtained the green light from the FDA, which is a big deal that will positively impact revenues. The stock used to trade near $20 in 2019, and it might return to its glory days thanks to the FDA designation.https://twitter.com/SteveYonezu/status/1489224081069129728

PENNY STOCKS #2 SENS

Senseonics Holdings Inc is another stock moved by FDA-related news. The NYSE American-listed stock is now trading at $3.35, up 40% during the last five trading sessions. This is the highest level since the end of November 2021. The stock couldn’t consolidate above the $4 mark last year, and it now has the chance to finally break that resistance on some meaningful update from the FDA.The $1.5 billion company develops and sells continuous glucose monitoring (CGM) systems for people with diabetes in the US, Europe, the Middle East, and Africa. Its products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. https://www.ascensiadiabetes.com/eversense/eversense-cgm-systemSENS is collaborating with Ascensia when it comes to marketing and distribution. The Eversense device will benefit from Ascensia’s large footprint in Medicare and allow them to do the heavy lifting on Senseonic’s behalf.The last time we covered SENS in August last year, it was trading at relatively the same level. Nevertheless, now there are more reasons to anticipate a long-term bullish ascension.Last month, the company said the FDA’s review for the PMA supplement for the next generation Eversense 180-day CGM system is nearing completion. All queries have been answered and a decision regarding approval is expected in the coming weeks. Previously, the FDA approved SENS’ 90-day system.SENS CEO Tim Goodnow said:

“We understand that the FDA is at full capacity managing the backlog of COVID-19 related filings creating longer than expected review timelines. We are confident a decision regarding approval of the 180-day system will be made in the coming weeks as the FDA continues to clear out the backlog. In 2021 we integrated operations and coordination activities with our commercial collaborator Ascensia Diabetes Care. A thoughtful go-to-market strategy is being designed to target a smooth transition to the 180-day system while providing uninterrupted service for patients, providers and payors. We are excited to advance long-term solutions for people with diabetes as we continue to aim to make the new 180-day system available in the US.”

Judging by the job posting from Ascensia, it seems that FDA is ready to approve the new system, and the company is ready for its marketing effort.https://twitter.com/JustTasi/status/1489632451253129225SENS may be a good stock to hold with a long-term target. We think the price is undervalued at this point. We like that the public holds only 44% of shares, with the rest of the stock being distributed among insiders, companies, and institutional investors.

PENNY STOCKS #3 SFIO

Starfleet Innotech, Inc has been on the rise this week, gaining about 40% since Monday to trade at $0.032. The OTC stock used to trade near $0.1 last year, so there is much room for growth.SFIO is an asset management company focused on innovation through disruptive collaborations across the three key industries: Food and Beverage (F&B), Real Estate, and Technology. It currently operates in New Zealand, Australia, and the Philippines. It is also expanding in the US by opening 50 epiphany cafes on top of its 30 cafes in New Zealand and 200+ worldwide.SFIO's key industries represent a clear roadmap of acquisition, consolidation, transformation, and expansion.Earlier this year, the $45 million company said that it was changing its name from Smokefree Innotec, Inc. SFIO is about to restructure its business this year, as it has big ambitions and is seeking to uplist to NASDAQ within the next three years.Last week, SFIO said that it had received a letter of interest from the Export-Import Bank of the United States (EXIM), in support of its real estate development projects in the Philippines. EXIM, the official export credit agency of the US, expressed interest in extending financing of up to $28.75 million, towards SFIO’s medical and retirement resort in Montemaria, Batangas, just south of Metro Manila in the Philippines. Potential debt financing from EXIM would be eligible for a maximum repayment term of seven years.This follows a series of partnerships and exploratory talks SFIO has spearheaded towards non-dilutive debt financing for its various projects. SFIO is currently engaged with a number of local banks in the Philippines to secure similar financing arrangements for their real estate developments, including a bayside, eco-friendly tech village in Batangas.Profits from these high-yield projects are intended to be reinvested into future growth.On Tuesday, the company presented the members of its newly formed advisory board.Everything about SFIO points to expansion and rapid growth, which makes this Pink Current stock a good buy. With over $200 million in property development projects and $24 million revenue in 2021, three pennies is definitely not a fair price.https://twitter.com/ValueTrader1987/status/1489375612338774016The company aims for $100 million in revenue this year and plans to uplist to OTCQB by the end of the year, so make sure to keep an eye on it because SFIO is about to explode.

PENNY STOCKS #4 VXIT

VirExit Technologies, Inc started the year with new forces after bottoming out at the end of last year when it touched $0.0022 on December 30. The OTC stock has surged about 50% since Monday alone, currently trading at $0.0066.The Virexit brand pioneers innovative, effective, ethical, and safe products within the antiviral space. In 2020, VXIT purchased Safer Place Technologies, LLC, whose purpose is to create a primary sales and marketing platform as a vertical online marketplace.Last month, the company said in its annual report that it was about to launch its proprietary wellness, health and safety portal, entitled The VLife. The portal will be aimed at both corporations and consumers. Experts on this heavily content-driven site will address numerous aspects of today’s greatest challenges: returning to work safely, maintaining a mindful and productive state, and the effective exercising of safety precautions. The portal is the second phase of VirExit’s three-pronged approach to the future. The third offering will be announced soon.VXIT also said in its report that it was in negotiations regarding the possible purchase of Lexian Products, Inc. and its proprietary UV products.Last month, investors found out about VXIT’s capitalization effort that priced its stock at $0.02 per share, which is three times higher than today’s price. Also, the company has plans to uplist to NASDAQ.https://twitter.com/Richie32265731/status/1489272140524367880VXIT’s growth strategy focuses on financing for acquisitions from a value perspective, targeting valuations of approximately 6 to 8 times the 12-month forward cash flow to ensure acquisitions are immediately accretive to its earnings. Leveraging its existing scalable management platform, the company expects to achieve cost synergies post-acquisition by reducing the corporate overhead of the acquisition – most notably in the legal, accounting, and finance functions.After breaking above the 10 cents mark one year ago, VXIT was under constant bearish pressure in 2021, losing over 90% of its value. Now it’s time to recover losses and resume its march higher. VXIT looks to be a discount entry opportunity at current prices.

THE FINAL NOTE

Now is a great opportunity to invest in top penny stocks with great potential. Our job is to identify the best penny stocks with strong fundamentals and let our subscribers pick the ones they like to build a well-diversified portfolio.Buying dips and selling rips as swing trades remains the best strategy in the stock market. Still, whenever a hot stock is in the middle of a bull run, we recommend our subscribers to book profits.It’s very important to eye penny stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.Remember, all you need is one or two penny stocks to run in order to crush the market averages.As always, good luck to all (except the shorts)!

WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!

Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.